CLINICAL TRIALS PROFILE FOR VEMLIDY

All Clinical Trials for VEMLIDY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03241641 ↗	Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.	Completed	Konkuk University Medical Center	Phase 4	2017-10-26	Treatment of CHB patients with genotypic resistance to NUCs has been problematic due to the lack of data from randomized trials. Recently, two randomized trials comparing the efficacy of TDF monotherapy versus TDF and ETV combination therapy in CHB patients with documented genotypic resistance to adefovir (ADV) or ETV demonstrated TDF monotherapy was not statistically different in viral suppression at week 48 of treatment.1,2 The extension study based on the above two trials merged study subjects from these trials with changing from TDF and ETV combination group to TDF monotherapy to evaluate long-term efficacy and safety of TDF monotherapy for multidrug-resistant patients. At the time of merging of 192 subjects, by intention-to-treat analysis, 66.3% of TDF group and 68.0% of TDF-ETV group had virological response as determined by serum HBV DNA
NCT03241641 ↗	Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.	Completed	Korea University Guro Hospital	Phase 4	2017-10-26	Treatment of CHB patients with genotypic resistance to NUCs has been problematic due to the lack of data from randomized trials. Recently, two randomized trials comparing the efficacy of TDF monotherapy versus TDF and ETV combination therapy in CHB patients with documented genotypic resistance to adefovir (ADV) or ETV demonstrated TDF monotherapy was not statistically different in viral suppression at week 48 of treatment.1,2 The extension study based on the above two trials merged study subjects from these trials with changing from TDF and ETV combination group to TDF monotherapy to evaluate long-term efficacy and safety of TDF monotherapy for multidrug-resistant patients. At the time of merging of 192 subjects, by intention-to-treat analysis, 66.3% of TDF group and 68.0% of TDF-ETV group had virological response as determined by serum HBV DNA
NCT03241641 ↗	Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.	Completed	Samsung Medical Center	Phase 4	2017-10-26	Treatment of CHB patients with genotypic resistance to NUCs has been problematic due to the lack of data from randomized trials. Recently, two randomized trials comparing the efficacy of TDF monotherapy versus TDF and ETV combination therapy in CHB patients with documented genotypic resistance to adefovir (ADV) or ETV demonstrated TDF monotherapy was not statistically different in viral suppression at week 48 of treatment.1,2 The extension study based on the above two trials merged study subjects from these trials with changing from TDF and ETV combination group to TDF monotherapy to evaluate long-term efficacy and safety of TDF monotherapy for multidrug-resistant patients. At the time of merging of 192 subjects, by intention-to-treat analysis, 66.3% of TDF group and 68.0% of TDF-ETV group had virological response as determined by serum HBV DNA
NCT03241641 ↗	Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.	Completed	Seoul National University Hospital	Phase 4	2017-10-26	Treatment of CHB patients with genotypic resistance to NUCs has been problematic due to the lack of data from randomized trials. Recently, two randomized trials comparing the efficacy of TDF monotherapy versus TDF and ETV combination therapy in CHB patients with documented genotypic resistance to adefovir (ADV) or ETV demonstrated TDF monotherapy was not statistically different in viral suppression at week 48 of treatment.1,2 The extension study based on the above two trials merged study subjects from these trials with changing from TDF and ETV combination group to TDF monotherapy to evaluate long-term efficacy and safety of TDF monotherapy for multidrug-resistant patients. At the time of merging of 192 subjects, by intention-to-treat analysis, 66.3% of TDF group and 68.0% of TDF-ETV group had virological response as determined by serum HBV DNA
NCT03241641 ↗	Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.	Completed	Young-Suk Lim	Phase 4	2017-10-26	Treatment of CHB patients with genotypic resistance to NUCs has been problematic due to the lack of data from randomized trials. Recently, two randomized trials comparing the efficacy of TDF monotherapy versus TDF and ETV combination therapy in CHB patients with documented genotypic resistance to adefovir (ADV) or ETV demonstrated TDF monotherapy was not statistically different in viral suppression at week 48 of treatment.1,2 The extension study based on the above two trials merged study subjects from these trials with changing from TDF and ETV combination group to TDF monotherapy to evaluate long-term efficacy and safety of TDF monotherapy for multidrug-resistant patients. At the time of merging of 192 subjects, by intention-to-treat analysis, 66.3% of TDF group and 68.0% of TDF-ETV group had virological response as determined by serum HBV DNA
NCT03471624 ↗	Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)	Active, not recruiting	Gilead Sciences	Phase 4	2018-05-01	Primary Objective: To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV (hepatitis B virus) treatment
NCT03471624 ↗	Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)	Active, not recruiting	Stanford University	Phase 4	2018-05-01	Primary Objective: To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV (hepatitis B virus) treatment

Clinical Trial Conditions for VEMLIDY

Condition Name

Condition Name for VEMLIDY
Intervention	Trials
Chronic Hepatitis b	6
Hepatitis B	5
Hepatitis B, Chronic	4
HBV	3

Condition MeSH

Condition MeSH for VEMLIDY
Intervention	Trials
Hepatitis B	15
Hepatitis	15
Hepatitis A	13
Hepatitis B, Chronic	11

Clinical Trial Locations for VEMLIDY

Trials by Country

Trials by Country for VEMLIDY
Location	Trials
China	17
Taiwan	4
Korea, Republic of	4
Hong Kong	2
Japan	1

Trials by US State

Trials by US State for VEMLIDY
Location	Trials
California	1

Clinical Trial Progress for VEMLIDY

Clinical Trial Phase

Clinical Trial Phase for VEMLIDY
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	7
Phase 2	4

Clinical Trial Status

Clinical Trial Status for VEMLIDY
Clinical Trial Phase	Trials
Recruiting	9
Not yet recruiting	6
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for VEMLIDY

Sponsor Name

Sponsor Name for VEMLIDY
Sponsor	Trials
Third Affiliated Hospital, Sun Yat-Sen University	5
Young-Suk Lim	2
Chiayi Christian Hospital	2

Sponsor Type

Sponsor Type for VEMLIDY
Sponsor	Trials
Other	47
Industry	9

VEMLIDY Market Analysis and Financial Projection

Last updated: April 28, 2026

Vemlidy (tenofovir alafenamide): clinical-trials update, market analysis, and projections

What is Vemlidy and what pipeline matters right now?

Vemlidy is tenofovir alafenamide (TAF), a nucleotide reverse transcriptase inhibitor approved for hepatitis B. Its commercial base is driven by:

• Chronic hepatitis B (CHB) treatment (including compensated and decompensated disease, with specific labeling tied to patient populations and renal/hematologic considerations).
• Renal-sparing positioning vs TDF (tenofovir disoproxil fumarate), which supports persistence in long-duration therapy.

The clinical value proposition remains linked to: (1) durable viral suppression, (2) renal and bone safety profile relative to older tenofovir regimens, and (3) compatibility with combination strategies in difficult HBV subpopulations (e.g., advanced fibrosis/cirrhosis).

What do the pivotal and ongoing HBV studies show (core efficacy and safety pillars)?

Vemlidy’s standing evidence base in HBV is anchored by Phase 3 outcomes in treatment-naïve and virologically suppressed patients and long-term follow-up.

Key efficacy/safety characteristics that underpin market access and guideline adoption

• Durable HBV DNA suppression across major HBV treatment populations.
• Safety profile emphasizing renal and bone improvements compared with TDF-based regimens in comparative programs (consistent across development reporting and guideline interpretations).
• Low discontinuation rates tied to tolerability in routine long-term use.

Why this matters commercially

• HBV is a lifelong or long-duration indication. In mature markets, retention and switching friction usually drive share stability more than marginal incremental efficacy.

What is the realistic “clinical trials update” picture for Vemlidy?

Vemlidy’s clinical cadence is best characterized as maintenance and lifecycle development rather than fundamental new-efficacy pivots. In practical terms, ongoing effort tends to focus on:

• Label expansion and subpopulation refinement (renal impairment, decompensated liver disease, special populations)
• Long-term safety/real-world evidence
• Head-to-head positioning versus TDF and regimen comparisons in HBV treatment sequencing

Under that structure, near-term trial impact typically comes from:

• Regulatory label updates in specific geographies and patient strata
• Post-marketing safety analyses (renal markers, bone density, discontinuation)
• Comparative strategy data that supports guideline preference and payer formulary placement

What does the market look like now: sizing, drivers, and competitive pressure?

TAF’s HBV franchise competes primarily within the HBV nucleos(t)ide analog class, with the main comparator set including TDF and older agents used in CHB. Commercial dynamics are shaped by payer preferences, renal-bone risk management, and guideline adherence.

Demand drivers

• High global CHB prevalence and ongoing diagnosis programs.
• Long-duration treatment and low turnover.
• Renal risk management: clinicians shift toward TAF in patients where TDF renal/bone effects raise treatment concerns.
• Decompensated cirrhosis use cases where tolerability and monitoring constraints influence agent selection.

Competitive landscape

• Primary “switch pressure”: TDF (and generics where pricing undercuts branded therapy).
• Second-order pressure: other HBV nucleos(t)ide agents (depending on region-specific formularies and pricing).

Reimbursement and access

In most markets, Vemlidy’s value case is judged against:

• TAF vs TDF risk-benefit (kidney and bone)
• Total cost of care (monitoring intensity and adverse event management)
• Patient adherence and persistence

Where is share likely to hold vs erode?

Share holding factors

• Patient-level switching inertia once stable on therapy.
• Guideline anchoring for TAF-based strategies in patients with renal/bone risk.
• Clinician preference where lab monitoring burden and tolerability drive regimen choice.

Share erosion factors

• Generic TDF penetration that compresses price differentials.
• Payer formulary controls limiting access unless renal impairment or bone-risk thresholds are met.
• Local competitor substitution where contracts or bundle pricing tilt economics.

Market projection: base case, bull case, bear case

Projections for Vemlidy require transparent assumptions on: (a) HBV treated populations, (b) penetration of TAF vs TDF, (c) price/mix, and (d) competitive and generic dynamics. Without a specific dataset in this prompt, the only defensible approach is to provide scenario structure rather than fabricated point forecasts.

Base case (most likely trajectory)

• Steady-to-moderate growth driven by:
  • continued diagnosis and treated-patient expansion
  • ongoing TAF share capture in renal/bone-risk cohorts
  • persistence on therapy
• Price pressure stays present, but not dominant enough to force broad switching.

Bear case (accelerated TDF/generic-driven substitution)

• Slower growth or flat revenue if:
  • payers expand TDF-first policies beyond renal/bone-risk criteria
  • formulary restrictions reduce TAF access
  • competition intensifies in major tender markets

Bull case (higher TAF penetration + label/strategy tailwinds)

• Faster growth if:
  • broader guideline-aligned use expands eligible patient pool for TAF
  • decompensated and complex subpopulation adoption increases
  • real-world persistence and safety messaging reduce switching

What policy and lifecycle events can change the projection?

Key structural variables that tend to shift commercial curves for mature HBV brands:

• Patent and exclusivity cliffs by jurisdiction (brand vs generic erosion)
• Formulary and tender mechanisms in countries with bulk purchasing
• Switch-to-generic thresholds set by payers (renal function cutoffs, bone risk criteria)
• New combination strategies that re-rank regimen selection

Key patent and exclusivity watchpoints that influence forward revenue

TAF is a known mature platform, and major earnings sensitivity typically comes from:

• Jurisdiction-specific exclusivity outcomes (brand-only period, data exclusivity scope)
• Generic entry timing and the “dose-form and presentation” specificities that determine substitution speed

Business implications for R&D and investment

For stakeholders evaluating Vemlidy or tenofovir successor strategies, the actionable implications are:

• HBV treatment is driven by long-term persistence and tolerability-based regimen selection, not short-term efficacy differentiation.
• Mature TAF revenue trajectories respond most to:
  • access controls (formularies, tenders)
  • generic substitution dynamics for comparators
  • patient-level risk targeting (renal and bone profiles)

Key Takeaways

• Vemlidy (tenofovir alafenamide) is a mature HBV therapy with commercial strength tied to durable viral suppression and renal/bone tolerability relative to older tenofovir approaches.
• The clinical development picture is primarily lifecycle maintenance, with commercial impact from label refinements, long-term safety, and HBV strategy positioning rather than “new MOA breakthroughs.”
• Market direction in 2025-2028 is driven by TAF vs TDF share dynamics, payer formulary/tender decisions, and the pace of generic substitution pressure.
• Forward revenue outcomes are best managed as scenario-dependent on exclusivity and access rather than assuming smooth linear growth.

---

FAQs

1) Why does Vemlidy maintain share in mature markets?

Because HBV therapy is long duration and clinicians select agents based on tolerability and monitoring burden; once stabilized, switching rates are usually low.

2) What is the main commercial comparator set for Vemlidy?

Tenofovir disoproxil fumarate (TDF) and other nucleos(t)ide analogs, with generic TDF pricing often exerting the strongest substitution pressure.

3) What clinical evidence categories most influence payer decisions for Vemlidy?

Long-term virologic durability plus renal and bone safety evidence that supports reduced adverse event management and monitoring intensity.

4) What trial themes are most likely to move Vemlidy’s label or uptake?

Subpopulation refinements, long-term outcomes, and evidence supporting treatment sequencing in advanced or difficult HBV settings.

5) What is the biggest risk to near-term Vemlidy revenue growth?

Expanded payer restrictions and faster-than-expected generic-driven substitution of comparator therapies that compress the price differential.

---

References

[1] Gilead Sciences. Vemlidy (tenofovir alafenamide) prescribing information.
[2] AASLD/IDSA/major guideline publications on chronic hepatitis B nucleos(t)ide analog selection (TAF vs TDF considerations).
[3] Clinical trial publications for tenofovir alafenamide in hepatitis B, including Phase 3 and long-term follow-up datasets.